摘要:
The present invention relates to improved diagnostic agents for Magnetic Resonance Imaging and optical imaging. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bioactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compositions comprising these agents and to methods of using the agents and compositions comprising the agents.
摘要:
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
摘要:
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
摘要:
The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
摘要:
FIG. 1 is a perspective view of a clamp; FIG. 2 is a front view thereof; FIG. 3 is a right side view thereof; FIG. 4 is a left side view thereof; FIG. 5 is a rear view thereof; FIG. 6 is a perspective view of the clamp when viewed from the top left side; FIG. 7 is a perspective view of the clamp when viewed from the top right side; FIG. 8 is a perspective view of the clamp when viewed from the bottom left side; FIG. 9 is a perspective view of the clamp when viewed from the bottom right side; FIG. 10 is a top view of the clamp; FIG. 11 is a bottom view of the clamp; and, FIG. 12 is an exploded view of the clamp.
摘要:
Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.
摘要:
Beverage brewing devices having a brewing unit having a brewing chamber and a closure mechanism, the closure mechanism having an open and closed orientation and a pod holder configured to hold a pod containing an extractable material, the pod having a peripheral flange, wherein the pod holder has a cup, a ledge extending substantially horizontally from the cup in an outward direction, and a gasket connected to the ledge about the cup, wherein, when the closure mechanism is in the closed orientation, a seal is created between the peripheral flange of the pod and the gasket of the pod holder to prevent bypass of liquid around the pod.
摘要:
A liquid mixture for producing a substantially gluten-free beer that conforms to Jewish Orthodox law is provided. The liquid mixture may include a base of filtered water, at least two sugars, wherein the two sugars are honey and molasses. The liquid mixture may also include a bittering agent, wherein the bittering agent is obtained from a plurality of hops, and wherein the hops are obtained from the group consisting of Centennial hops, Perle hops, Saaz hops, and Hallertauer hops. The liquid mixture may further include a protein coagulant, a yeast nutrient, and a plurality of yeast cells.
摘要:
The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.